Oral Wegovy vs. Compounded Oral Semaglutide: The 6-Month Verdict

Oral Wegovy launched in January 2026. Six months later, how does the first FDA-approved GLP-1 weight loss pill stack up against compounded alternatives?

The Oral GLP-1 Landscape Has Changed

When the FDA approved oral Wegovy (semaglutide 25 mg tablets) in December 2025, it marked a genuine milestone: the first oral GLP-1 receptor agonist approved specifically for weight management. Novo Nordisk launched it in U.S. pharmacies on January 5, 2026, starting at $149/month for the 1.5 mg introductory dose through savings programs.

The OASIS 4 trial showed approximately 17% mean weight loss at 64 weeks in adherent patients (about 14% in the broader intent-to-treat population). Those numbers are competitive with injectable semaglutide, and the convenience of a daily pill versus a weekly injection is meaningful for the millions of people who find needles to be a genuine barrier.

But oral Wegovy doesn't exist in a vacuum. Compounded oral semaglutide — primarily sublingual tablets and troches — has been available through telehealth platforms and compounding pharmacies for over a year. The comparison matters because the FDA's proposed 503B exclusion (comment period closing June 29, 2026) could eliminate many compounded options entirely.

The Head-to-Head Comparison

Efficacy

Oral Wegovy's efficacy is well-documented through the OASIS clinical program. The 25 mg daily dose delivers weight loss comparable to the injectable 2.4 mg weekly dose, though with a more gradual onset due to the titration schedule.

Compounded oral semaglutide is harder to evaluate because there are no standardized clinical trials. Compounding pharmacies produce sublingual tablets and troches in varying doses and formulations. Bioavailability of sublingual semaglutide is generally lower than the proprietary SNAC-enhanced oral formulation in Wegovy tablets, which means doses must be higher to achieve similar blood levels. Some providers report comparable patient outcomes, but the evidence is anecdotal rather than clinical.

Pricing

This is where things get interesting. Oral Wegovy's list price is in line with injectable Wegovy (~$1,300/month), but the manufacturer savings program brings the starting dose down to $149/month. The maintenance dose (25 mg) pricing through savings programs varies by insurance status and eligibility.

Compounded oral semaglutide typically runs $150–350/month depending on the provider and dose, with no insurance involvement. For cash-pay patients without insurance coverage, compounded options have historically been significantly cheaper than brand-name pricing — though not necessarily cheaper than the savings program pricing.

Availability and Convenience

Oral Wegovy is available at major retail pharmacies through prescription. The daily dosing requires taking the pill on an empty stomach with a small amount of water, then waiting at least 30 minutes before eating or drinking. This is identical to the existing Rybelsus protocol.

Compounded oral options are shipped directly from compounding pharmacies, typically via telehealth prescriptions. Storage is often more straightforward (room temperature for troches), though formulations vary.

Regulatory Risk

Here's the decisive factor: the FDA's April 30, 2026 proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B Bulks List. If finalized (expected Q3 2026), large-scale compounding of these drugs ends permanently. 503A patient-specific compounding would remain legal, but at significantly reduced scale and potentially higher cost.

Oral Wegovy faces no such regulatory risk. It's an FDA-approved medication from a major manufacturer with robust supply chains.

Our Verdict

For patients choosing today with a long-term perspective, oral Wegovy is the more defensible choice. The clinical evidence is solid, the regulatory position is unassailable, and manufacturer savings programs make the pricing competitive with compounded alternatives. The daily dosing is the main trade-off versus weekly injectable options.

Compounded oral semaglutide remains a viable option through 2026, particularly for patients already established on a working protocol. But the regulatory writing is on the wall, and building a treatment plan around compounded access carries real continuity risk.